. Author manuscript; available in PMC: 2012 Jan 1.

Published in final edited form as: Pharmacogenomics. 2011 Mar;12(3):327–339. doi: 10.2217/pgs.10.191

Table 2.

Pharmacological and outcome variables used in the PROMISE analysis in AML97 (discovery cohort) PR4 and AML02 (validation cohort) PR3 analysis.

Variable	Median (range)	Median (range)
Discovery cohort AML97	Arm A	Arm B
Day 1 Ara-CTP	0.28 (0.09–2.43)	0.22 (0.01–0.88)
DNA synthesis (100^† day1/baseline)	8.06 (1.27–62.59)	19.7 (2.4–148)
OS^†	0.368 (0.104)	0.565 (0.10)
EFS^†	0.368 (0.104)	0.522 (0.10)
Validation cohort AML02	HDAC arm	LDAC arm
IC₅₀	0.28 (0.01–5.0)	0.394 (0.0055–5.0)
Day 22 MRD^†	12 neg, 4 int, 5 high	15 neg, 2 int, 8 high
OS^‡	0.905 (0.068)	0.706 (0.102)
EFS^‡	0.857 (0.081)	0.640 (0.111)

Intermediate: 0.1% ≤ MRD ≤ 1%; High: MRD >1%.

^†

5-year OS or EFS estimates with Peto and Pike standard error.

^‡

3-year OS or EFS estimates with Peto and Pike standard error.

Ara-CTP: Cytarabine 5´-triphosphate; EFS: Event-free survival; HDAC: High-dose cytarabine; Int: Intermediate;

LDAC: Low-dose cytarabine; MRD: Minimal residual disease; Neg: Negative; OS: Overall survival; PROMISE: Projection onto the Most Interesting Statistical Evidence.